L. Buonaguro

HCV-related hepatocellular carcinoma: gene signatures associated with TERT promoter mutations and sex
20253 citationsauthor #10
Cross-reactive CD8+ T cell responses to tumor-associated antigens (TAAs) and homologous microbiota-derived antigens (MoAs)
202410 citationsauthor #13
Development of a cell penetrating peptide carrying a biological active HPV16 E6 inhibitory molecule for delivery into cervical cancer cells
20240 citationsauthor #9
Emerging role of endogenous peptides encoded by non-coding RNAs in cancer biology
202410 citationsauthor #9
Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations
202328 citationsauthor #8
Immune profiling of SARS-CoV-2 epitopes in asymptomatic and symptomatic pediatric and adult patients
20235 citationsauthor #17
Peptide-based vaccine for cancer therapies
202384 citationsauthor #1
Microorganisms-derived antigens for preventive anti-cancer vaccines.
20238 citationsauthor #1
Integrated plasma metabolomics and lipidomics profiling highlights distinctive signature of hepatocellular carcinoma in HCV patients
202326 citationsauthor #10
Sorafenib-Loaded PLGA Carriers for Enhanced Drug Delivery and Cellular Uptake in Liver Cancer Cells
202318 citationsauthor #13
Molecular mimicry and cancer vaccine development
202342 citationsauthor #7
The impact of antigenic molecular mimicry on anti-cancer T-cell immune response
20227 citationsauthor #2
MEMORY T CELLS ELICITED BY MICROORGANISMS CROSS-REACT WITH TUMOR-ASSOCIATED ANTIGENS
20220 citationsauthor #1
Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT – IRCCS “Fondazione Pascale” Cancer Center (Naples, Italy)
20226 citationsauthor #5
Antigenic molecular mimicry in viral-mediated protection from cancer: the HIV case
20228 citationsauthor #11
Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT – IRCCS “Fondazione Pascale” Cancer Center (Naples, Italy)
20220 citationsauthor #5
Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021
20224 citationsauthor #7
Phase I/II multicenter trial of a novel therapeutic cancer vaccine, HepaVac-101, for hepatocellular carcinoma.
202256 citationsauthor #35
Molecular mimicry between tumor associated antigens and microbiota-derived epitopes
20221 citationsauthor #8
Three doses of BNT162b2 COVID-19 mRNA vaccine establish long-lasting CD8+ T cell immunity in CLL and MDS patients
202214 citationsauthor #7
Mutations in the telomerase reverse transcriptase promoter and PIK3CA gene are common events in penile squamous cell carcinoma of Italian and Ugandan patients
20228 citationsauthor #6
1175 Memory T cells elicited by microorganisms cross-react with tumor-associated antigens
20220 citationsauthor #1
P03.06 Tumor associated antigens and pathogen antigens: friends or foes
20220 citationsauthor #1
Virus-like Particles as Preventive and Therapeutic Cancer Vaccines
202258 citationsauthor #5
The Molecular Interplay between Human Oncoviruses and Telomerase in Cancer Development
202216 citationsauthor #7
Neoantigens as potential vaccines in hepatocellular carcinoma
202225 citationsauthor #16
Telomerase: a good target in hepatocellular carcinoma? An overview of relevant preclinical data
20224 citationsauthor #6
MEMORY T CELLS ELICITED BY MICROORGANISMS CROSS-REACT WITH TUMOR-ASSOCIATED ANTIGENS
20220 citationsauthor #1
Long-term memory T cells as preventive anticancer immunity elicited by TuA-derived heteroclitic peptides
20210 citationsauthor #10
Identification and characterization of heteroclitic peptides in TCR-binding positions with improved HLA-binding efficacy
202112 citationsauthor #9
Human Endogenous Retrovirus Reactivation: Implications for Cancer Immunotherapy
202124 citationsauthor #7
HLA Does Not Impact on Short-Medium-Term Antibody Response to Preventive Anti-SARS-Cov-2 Vaccine
202120 citationsauthor #12
Long-term memory T cells as preventive anticancer immunity elicited by TuA-derived heteroclitic peptides
20216 citationsauthor #10
Novel Molecular Targets for Hepatocellular Carcinoma
202114 citationsauthor #10
Clinical Significance of Telomerase Reverse-Transcriptase Promoter Mutations in Hepatocellular Carcinoma
202118 citationsauthor #5
Identification and characterization of heteroclitic peptides in TCR-binding positions with improved HLA-binding efficacy
20210 citationsauthor #9
MHC-Optimized Peptide Scaffold for Improved Antigen Presentation and Anti-Tumor Response
20217 citationsauthor #17
Profiling the HCV immune response in patients with chronic liver diseases and hepatocellular carcinoma by peptide microarray analysis.
20211 citationsauthor #7
Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs).
202156 citationsauthor #12
The Role of RNA Splicing Factors in Cancer: Regulation of Viral and Human Gene Expression in Human Papillomavirus-Related Cervical Cancer
202051 citationsauthor #2
Pathogens: Our Allies against Cancer?
20209 citationsauthor #1
High somatic mutation and neoantigen burden do not correlate with decreased progression-free survival in HCC patients
20200 citationsauthor #9
A Nine-Gene Signature for Predicting the Response to Preoperative Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer
202026 citationsauthor #14
SARS-CoV-2 RNA polymerase as target for antiviral therapy
20200 citationsauthor #1
Human Hepatocellular Carcinoma (HCC)
202010 citationsauthor #1
Editorial: Novel Strategies for Anti-Tumor Vaccines
20208 citationsauthor #2
Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment
20200 citationsauthor #1
Cell Surface Proteins in Hepatocellular Carcinoma: From Bench to Bedside
202010 citationsauthor #3
Antimicrobial Peptides as Anticancer Agents: Functional Properties and Biological Activities
2020320 citationsauthor #3
The Clinical and Translational Research Activities at the INT – IRCCS “Fondazione Pascale” Center (Naples, Italy) during the COVID-19 Pandemic
20200 citationsauthor #25
Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma
20200 citationsauthor #28
Selecting Target Antigens for Cancer Vaccine Development
2020111 citationsauthor #1
Covid‐19: Time for a paradigm change
202052 citationsauthor #4
Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment
202010 citationsauthor #1
The clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic
20207 citationsauthor #25
Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker
202016 citationsauthor #13
Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy
202040 citationsauthor #16
Identification of neoantigens as potential vaccines in hepatocellular carcinoma
20200 citationsauthor #10
The Role of microRNAs, Long Non-coding RNAs, and Circular RNAs in Cervical Cancer
2020188 citationsauthor #3
COVID-19: A Paradigm Change
20204 citationsauthor #3
SARS-CoV-2 RNA polymerase as target for antiviral therapy
202070 citationsauthor #1
The clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic
20200 citationsauthor #25
Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy
202010 citationsauthor #13
Abstract LB-094: Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma
20203 citationsauthor #1
Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines
202058 citationsauthor #5
Uncovering “hidden” mutations in hepatocellular carcinoma: the use of droplet digital PCR to detect TERT promoter mutations
20190 citationsauthor #5
Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.
201933 citationsauthor #7
Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma
2019114 citationsauthor #27
Immunotherapy in hepatocellular carcinoma.
201976 citationsauthor #1
Abstract 1198: Neoantigen load, tumor immune infiltration and prediction of survival in HCC patients
20190 citationsauthor #8
High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy
201935 citationsauthor #9
The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma
201862 citationsauthor #2
Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)
201813 citationsauthor #3
Abstract CT057: Phase I trial to evaluate the feasibility and safety of an individualized peptide vaccine of unmodified cancer antigens: PepIVAC-01
20181 citationsauthor #8
Telomerase promoter mutations in human immunodeficiency virus-related conjunctiva neoplasia
201813 citationsauthor #2
Cellular prognostic markers in hepatitis-related hepatocellular carcinoma
201819 citationsauthor #6
HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients.
201810 citationsauthor #1
Prevalence of “unclassified” HPV genotypes among women with abnormal cytology
20180 citationsauthor #8
Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients
201831 citationsauthor #12
Prevalence of “unclassified” HPV genotypes among women with abnormal cytology
201814 citationsauthor #8
Telomerase promoter mutations in human immunodeficiency virus-related conjunctiva neoplasia
20180 citationsauthor #2
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)
201815 citationsauthor #3
Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma
201840 citationsauthor #7
Human Oncoviruses and p53 Tumor Suppressor Pathway Deregulation at the Origin of Human Cancers
201875 citationsauthor #4
B-105 Discovery to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine - HEPAVAC
20180 citationsauthor #1
The Role of Sensing Peptides in the Cross-talk between Microbiota and Human Cancer Cells.
20186 citationsauthor #2
Potentiating cancer vaccine efficacy in liver cancer
201829 citationsauthor #6
Effect of electrochemotherapy on human herpesvirus 8 kinetics in classic Kaposi sarcoma
201712 citationsauthor #7
P-A5 Genetic and epigenetic changes as biomarkers of progression in HPV-related cancers
20170 citationsauthor #3
Virus-Like Particles
20171 citationsauthor #4
New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology
201760 citationsauthor #2
New vaccination strategies in liver cancer.
201723 citationsauthor #1
Use of adjuvants for immunotherapy
201731 citationsauthor #4
Discovery to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine adjuvanted with CV8102 (RNAdjuvant) – HEPAVAC
20171 citationsauthor #19
I-108 Discovery to first-in-man of a multi-peptide-based hepatocellular carcinoma vaccine adjuvanted with CV8102 (RNAdjuvant) - HEPAVAC
20170 citationsauthor #1
Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting
201723 citationsauthor #14
TERT promoter and CTNNB1 gene mutations represent cancer signatures specific for hepatitis B and hepatitis C related hepatocellular carcinoma
20170 citationsauthor #3
Vaccine Approaches in Hepatocellular Carcinoma
20171 citationsauthor #4
Corrigendum to "New vaccination strategies in liver cancer" [Cytokine Growth Factor Rev. 36 (2017) 125-129].
20171 citationsauthor #1
Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma
201734 citationsauthor #2

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT